Doc said "Only a sociopath can work in mass therapy".

Published Date: 02 Mar 2023

Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.

Read Full News

Latest News

Enhancing Clinical Efficiency with AI to Prioritize Patient Care, with Ellen Gelles, MD Ellen Gelles, MD

Gelles discussed AI tools that are becoming a part of clinician’s armamentariums and the impact they are having on the field.

Addressing Community Health Needs for Comprehensive Care, with Mindy Hoang, MD Mindy Hoang, MD

Hoang discussed the CARD initiative started at Wayne State University in Detroit that she presented at the ACP IM 2025 meeting.
HTTP error: 503

Experts Weigh Best Practices for Deprescribing

Nearly 3 in 10 Italians older than 65 years take more than 10 medications, highlighting why deprescribing is gaining attention as a strategy to improve care.

Experts Debate Combination Therapy for Pulmonary Fibrosis

Respiratory experts disagree over initiating upfront dual therapy vs sequential escalation as next-generation antifibrotics emerge for pulmonary fibrosis.

Keto Diet Boosts Liver Health More Than Others in Obesity

A ketogenic diet paired with weight loss improves liver health more than a Mediterranean or very low-fat diet with similar weight loss in people with metabolically unhealthy obesity.

Todays Updates

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Todays Updates

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Latest News

Gelles discussed AI tools that are becoming a part of clinician’s armamentariums and the impact they are having on the field.
HTTP error: 503HTTP error: 503

Nearly 3 in 10 Italians older than 65 years take more than 10 medications, highlighting why deprescribing is gaining attention as a strategy to improve care.

Respiratory experts disagree over initiating upfront dual therapy vs sequential escalation as next-generation antifibrotics emerge for pulmonary fibrosis.

A ketogenic diet paired with weight loss improves liver health more than a Mediterranean or very low-fat diet with similar weight loss in people with metabolically unhealthy obesity.

News All Time

HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503

Can Sexual Experience Reshape the Brain?

New research is exploring whether sexual experience may shape brain circuits linked to reward, learning, and mood — but the human evidence remains early.

Somatic Mutations Shape Systemic Autoinflammatory Disease

Acquired somatic variants may drive over 20% of systemic autoinflammatory disease diagnoses, with VEXAS syndrome and cryopyrin-associated periodic syndromes representing the majority of cases.

Sonographer Shortage Is Affecting Expectant Women’s Health

A sonographer shortage confronts expectant women in Ontario with long commutes for routine ultrasounds.
HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503

Long-Term Primary Care Saves Lives — and Is Hard to Achieve

New research quantifies the benefits of long-term patient relationships. How can you build them in a system that prioritizes high-volume access?

Size Matters for Chest Tubes

New data show similar outcomes with large-bore and small-bore chest tubes in patients with pneumothoraces.
HTTP error: 503

Rilzabrutinib May Be Promising in IgG4-Related Disease

Rilzabrutinib treatment is associated with a reduction in disease activity in patients with IgG4-related disease and enables most patients to discontinue glucocorticoids without experiencing flares.
HTTP error: 503

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

November 2023, Medical Bulletin 04/.

2.

Remote CBT for Insomnia Improves Symptoms During Chemo

3.

Vaccine shows promise for pancreatic cancer, study finds

4.

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training

5.

Some low-grade prostate cancers carry higher risks than biopsy suggests

1.

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions

2.

Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed

3.

Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor

4.

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer

5.

The importance of understanding normal serum osmolality

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

3.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot